Sai Life Sciences Limited (BSE: 544306, NSE: SAILIFE), a leading Indian Contract Research, Development and Manufacturing Organization (CRDMO), announced its financial results for the third quarter and nine months ended December 2025. The company delivered robust growth, driven by demand in CRO and CDMO services.
Q3 FY26 Financial Performance
Revenue from operations reached ₹556 crore in Q3 FY26, up 27% from ₹440 crore in Q3 FY25. This growth reflected strong contributions from both CRO and CDMO segments.
EBITDA increased 54% to ₹191 crore from ₹124 crore year-over-year, with margins expanding 605 basis points to 34%. This improvement stemmed from higher capacity utilization, operational efficiencies, and cost optimization.
Profit after tax (PAT) surged 86% to ₹100 crore, compared to ₹54 crore in the prior-year quarter, highlighting enhanced profitability.
9M FY26 Results
For the nine months ended December 2025, revenue from operations grew 43% to ₹1,590 crore from ₹1,115 crore in 9M FY25. EBITDA rose 79% to ₹472 crore, while PAT more than tripled, up 199% to ₹245 crore from ₹82 crore.
These figures outperformed broader CRDMO industry trends, supported by sustained demand and volume growth across key service lines.
Key Business Developments
Sai Life Sciences advanced its AI and digital platforms, applying AI-driven retrosynthetic analysis to machine learning-generated compounds for faster route design. The company delivered a full library of AI-designed macrocyclic peptides, showcasing AI’s role in complex modalities.
Technology adoption included a centralized group for photochemistry and electrochemistry, alongside strengthened flow capabilities in discovery and CMC. Automation efforts featured a permeability measurement platform, high-throughput experimentation in India, and continuous counter-current LLE scaling.
Capital expenditure totaled ₹405 crore as of the quarter-end, on track toward the FY26 plan of ₹700 crore, focusing on manufacturing and process development infrastructure.
Quality remained a priority, with eight customer audits completed across units, yielding zero data integrity deviations or critical observations.
Sustainability and Compliance Achievements
The company released its 6th Sustainability Report 2024–25, detailing ESG progress. It earned My Green Lab (MGL) Green-level certification for four laboratories—two PR&D and two Medicinal Chemistry—with over 98% compliance.
A joint case study with Bayer highlighted a hybrid solar-wind captive power model at the Bidar site via a long-term power purchase agreement.
Leadership Commentary
Krishna Kanumuri, Managing Director and CEO, stated that Q3 FY26 advanced the company’s science-led CRDMO positioning through AI, digital tools, and modern chemistry. Capacity expansions and talent additions align with client needs for complex programs.
Siva Chittor, Chief Financial Officer, emphasized disciplined execution driving outperformance, with capex reinforcing scalable infrastructure. A solid order pipeline positions Sai Life Sciences for sustained profitable growth.